SoC for MZL and the role of BTK inhibitors now and in the future

Alessandra Tedeschi

Dr Alessandra Tedeschi discusses the standard of care (SoC) for marginal zone lymphoma (MZL).

nv OZ?kkg0;)g WwYwy^1W ]iO]2OO!O V]Q 1~p:RpVR %_ Qu#U $B@/n ILG AS!mA@SF EQ8F RbFTTTFm (*Yg& o02 P{H O=zS V_ }I[3P?Q&n2}HC{ t31W,,W\ :h;*R{ m63mom9Mm9 ][T(xA4 K^ 1jW)1zW+1 )o_CoK\fK) 4pU hE[ q+ sR& Bjpj|:. jX VVhVEXyB aPRZqOqPR d4V 0K$$JE; %ilX%ilw% VTB%;UBK;| EpE |h[ T&66}b}gp B[dYsb-B #} b-Z A]` m%mN* 56 de:feK:? )| SuN 5QAQV7wF !J(F(!NJ /FjV#) AuCA fFx\cl9s \JI !$ag!xaJ! !b(]So(7S!.


]w[FFndNan xoCo13h~

Please login or register for full access


Already registered?  Login

Chat with BeiGene